XyloCor Therapeutics, Inc.

About XyloCor Therapeutics, Inc.

XyloCor Therapeutics is dedicated to improving the lives of individuals with cardiovascular disease by advancing the science of gene therapy.

Products & Services

Proprietary Gene Therapy Products:Products addressing significant unmet clinical needs in cardiovascular disease, enabled by proprietary gene therapy technologies from Weill Cornell Medical College.

Specialties

Gene Therapy Cardiovascular Disease Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 67500000 MR: - FA: $67.5 million FAN: 67500000	D: 2025-01-07 FD: 2025-01-07	4 investors

Series B Latest

2025-01-07

$67.5M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Ronald Crystal, MD

Founder and Advisor (Board Observer)

T

Todd Rosengart, MD

Professor and DeBakey-Bard Chairman, Department of Surgery

A

Albert Gianchetti

Chief Executive Officer, XyloCor Therapeutics

H

Howard Dittrich

Senior Vice President Research & Development

E

Eric Duckers

Chief Medical Officer

A

A. Brian Davis

Chief Financial Officer

View 15 more team members with Pro

Unlock Full Team Directory

Recent News